Is Novacyt SA halal to invest in?

According to Musaffa's Shariah screening methodology, Novacyt SA (ALNOV.PA) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Novacyt SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Novacyt SA using these criteria to determine its compliance status.

Can Muslims buy shares of Novacyt SA?

Muslim investors may consider investing in Novacyt SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Novacyt SA classified as NOT HALAL?

Musaffa determines the Shariah status of Novacyt SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Novacyt SA updated?

The Shariah compliance status of Novacyt SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Novacyt SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Novacyt SA?

You can check the latest Shariah compliance status of Novacyt SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Novacyt SA ALNOV.PA

€0.53 €0.02 (3.70%) 1D

Last Updated: May 15, 12:00 AM·XPAR

ALNOV.PA Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: July 28, 2025

Report Source: 2024 Annual Report

Novacyt SA. Stock Analysis ALNOV.PA

France Health Care Nano Cap Report: 2024 Annual

Novacyt SAS is a diagnostics company, which engages in the business of developing, producing, and selling vitro and molecular diagnostic tests and products for a wide range of infectious diseases. The company is headquartered in Velizy-Villacoublay, Ile-De-France. The company went IPO on 2012-10-12. The firm develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The company provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The firm develops secure automated cytology named NovaPrep Processor System. The company offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The company creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle.

Key Statistics of Novacyt SA (ALNOV.PA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€0.51€0.57

Today's Open

€0.51

Volume

190.74K

P/E Ratio (TTM)

52 Week Range

€0.29€1.04

Market Cap

22.97M

Avg. Volume

133.85K

Dividend Yield

Financial Metrics & Statements of Novacyt SA (ALNOV.PA)

FAQ's for Novacyt SA (ALNOV.PA)

According to Musaffa’s Shariah screening methodology, Novacyt SA (ALNOV.PA) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.